Definition: Early on during the development of acneiform eruption or with subsequent ﬂare-ups of the rash, scattered Telangiectasia may appear on the face and also behind the ears, on the chest, back and limbs, usually in sites that are or have been affected by papulopustules.1,2 Telangiectasia is characterised by local dilatation of small vessels resulting in red discoloration of the skin or Mucous membranes. Unlike other Telangiectasia, the lesions tend to fade over months and usually leave behind some hyperpigmentation.1
Onset: Several weeks after treatment initiation.
Resolution: Tend to fade over months following completion of EGFRI treatment and usually leave behind some hyperpigmentation.
- I78.9 Disease of capillaries, unspecified.
- Y43.8 Other drugs, medicaments and biological primarily systemic substances causing adverse effects in therapeutic use, not elsewhere classified.
Telangiectasias covering <10% BSA.
Telangiectasias covering >10% BSA; associated with psychosocial impact.
Typical clinical presentations of Telangiectasias can be viewed at the bottom of the page.
1Segaert S & Van Cutsem E. Ann Oncol 2005; 16: 1425-1433.
2Lacouture ME. Nat Rev Cancer 2006; 6: 803-812.
3European Medicine Agency. Tarceva® (erlotinib) Summary of Product Characteristics 2009.
4European Medicine Agency. Iressa® (gefitinib) Summary of Product Characteristics 2009.
5European Medicine Agency. Erbitux® (cetuximab) Summary of Product Characteristics 2009.
6European Medicine Agency. Vectibix® (panitumumab) Summary of Product Characteristics 2009.
7European Medicine Agency. Tyverb® (lapatinib) Summary of Product Characteristics 2010.